These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 8319521)

  • 41. Plasminogen activator inhibitor (PAI-1) activity is elevated in Asian and Caucasian subjects with non-insulin-dependent (type 2) diabetes but not in those with impaired glucose tolerance (IGT) or non-diabetic Asians.
    Nagi DK; Mohamed Ali V; Jain SK; Walji S; Yudkin JS
    Diabet Med; 1996 Jan; 13(1):59-64. PubMed ID: 8741814
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serum lipids and lipoproteins in type 2 diabetic patients with persistent microalbuminuria.
    Seghieri G; Alviggi L; Caselli P; De Giorgio LA; Breschi C; Gironi A; Niccolai M; Bartolomei GC
    Diabet Med; 1990 Nov; 7(9):810-4. PubMed ID: 2148134
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The influence of regional adiposity on atherogenic risk factors in men and women with type 2 diabetes.
    Baynes C; Henderson AD; Anyaoku V; Richmond W; Johnston DG; Elkeles RS
    Diabet Med; 1991 Jun; 8(5):458-63. PubMed ID: 1830532
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Patterns of glucose and lipid abnormalities in black NIDDM subjects.
    Chaiken RL; Banerji MA; Pasmantier R; Huey H; Hirsch S; Lebovitz HE
    Diabetes Care; 1991 Nov; 14(11):1036-42. PubMed ID: 1797484
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A very low-carbohydrate, low-saturated fat diet for type 2 diabetes management: a randomized trial.
    Tay J; Luscombe-Marsh ND; Thompson CH; Noakes M; Buckley JD; Wittert GA; Yancy WS; Brinkworth GD
    Diabetes Care; 2014 Nov; 37(11):2909-18. PubMed ID: 25071075
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Metabolic control affects plasma lipid and apolipoprotein levels in women, but not in men, with IDDM.
    Benzi L; Marchetti P; Giampietro O; Miccoli R; Pecori N; Sanna G; Caricato F; Giovannitti MG; Ciccarone AM; Navalesi R
    Acta Diabetol Lat; 1988; 25(2):149-54. PubMed ID: 3223190
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Albuminuria and 24-h ambulatory blood pressure in normoalbuminuric and microalbuminuric NIDDM patients. A longitudinal study.
    Nielsen S; Schmitz A; Poulsen PL; Hansen KW; Mogensen CE
    Diabetes Care; 1995 Nov; 18(11):1434-41. PubMed ID: 8722066
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Metabolic control and vascular diseases under oral antidiabetic drug versus insulin therapy and/or diet alone during the first year of hemodialysis in type 2 diabetic patients with ESRD.
    Biesenbach G; Bodlaj G; Ebner S; Biesenbach P; Pieringer H
    Int Urol Nephrol; 2011 Dec; 43(4):1155-60. PubMed ID: 20640938
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Apolipoprotein E polymorphism is associated with plasma cholesterol response in a 7-day hospitalization study for metabolic and dietary control in NIDDM.
    Murakami K; Shimizu M; Yamada N; Ishibashi S; Shimano H; Yazaki Y; Akanuma Y
    Diabetes Care; 1993 Apr; 16(4):564-9. PubMed ID: 8462379
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients.
    Halpern A; Mancini MC; Suplicy H; Zanella MT; Repetto G; Gross J; Jadzinsky M; Barranco J; Aschner P; Ramirez L; Matos AG
    Diabetes Obes Metab; 2003 May; 5(3):180-8. PubMed ID: 12681025
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.
    Yki-Järvinen H; Dressler A; Ziemen M;
    Diabetes Care; 2000 Aug; 23(8):1130-6. PubMed ID: 10937510
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MspI polymorphism at +83 bp in intron 1 of the human apolipoprotein A1 gene is associated with elevated levels of HDL cholesterol and apolipoprotein A1 in nondiabetic subjects but not in type 2 diabetic patients with coronary heart disease.
    Pulkkinen A; Viitanen L; Kareinen A; Lehto S; Laakso M
    Diabetes Care; 2000 Jun; 23(6):791-5. PubMed ID: 10840998
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lipid and lipoprotein patterns in type 2 non-obese diabetic patients. Do Lp(a) levels decrease with improved glycemic control in these patients?
    Alagözlü H; Gültekin F; Candan F
    Nutr Metab Cardiovasc Dis; 2000 Aug; 10(4):204-8. PubMed ID: 11079258
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy.
    Lam KS; Cheng IK; Janus ED; Pang RW
    Diabetologia; 1995 May; 38(5):604-9. PubMed ID: 7489845
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Improvement of glycaemic control in type 2 diabetes: favourable changes in blood pressure, total cholesterol and triglycerides, but not in HDL cholesterol, fibrinogen, Von Willebrand factor and (pro)insulin.
    Becker A; van der Does FE; van Hinsbergh VW; Heine RJ; Bouter LM; Stehouwer CD
    Neth J Med; 2003 Apr; 61(4):129-36. PubMed ID: 12852722
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sex-specific differences in metabolic control, cardiovascular risk, and interventions in patients with type 2 diabetes mellitus.
    Kautzky-Willer A; Kamyar MR; Gerhat D; Handisurya A; Stemer G; Hudson S; Luger A; Lemmens-Gruber R
    Gend Med; 2010 Dec; 7(6):571-83. PubMed ID: 21195357
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Relative fasting hypoinsulinaemia and ultrasonically measured early arterial disease in type 2 diabetes. The SENDCAP Study Group, St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention Study.
    Elkeles RS; Diamond JR; El-Bahghouti N; Dhanjil S; Nicolaides A; Geroulakos G; Renton S; Anyaoku V; Richmond W; Mather H; Sharp P
    Diabet Med; 1996 Mar; 13(3):247-53. PubMed ID: 8689846
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reversed circadian blood pressure rhythm is associated with occurrences of both fatal and nonfatal vascular events in NIDDM subjects.
    Nakano S; Fukuda M; Hotta F; Ito T; Ishii T; Kitazawa M; Nishizawa M; Kigoshi T; Uchida K
    Diabetes; 1998 Sep; 47(9):1501-6. PubMed ID: 9726241
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effects of enalapril and nifedipine on carbohydrate and lipid metabolism in NIDDM.
    Chan JC; Yeung VT; Leung DH; Tomlinson B; Nicholls MG; Cockram CS
    Diabetes Care; 1994 Aug; 17(8):859-62. PubMed ID: 7956631
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A controlled study of consumption of beta-glucan-enriched soups for 2 months by type 2 diabetic free-living subjects.
    Cugnet-Anceau C; Nazare JA; Biorklund M; Le Coquil E; Sassolas A; Sothier M; Holm J; Landin-Olsson M; Onning G; Laville M; Moulin P
    Br J Nutr; 2010 Feb; 103(3):422-8. PubMed ID: 19781120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.